{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Wang Z"],"funding":["Ministry of Science and Technology of the People&apos;s Republic of China"],"pagination":["20653-20663"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7439698"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["5(32)"],"pubmed_abstract":["Clinically diagnosing low-grade gliomas and microscopic metastatic tumors in the spinal cord using magnetic resonance imaging (MRI) is challenging, as the blood-brain barrier (BBB) almost completely excludes the MRI contrast agent gadopentetate dimeglumine, GdDTPA (Magnevist), from the brain. The development of a more efficient, safe, and broad-spectrum glioma diagnosis and treatment would therefore have a great clinical value. Based on the high expression levels of both transferrin receptor 1 (TfR1) and low-density lipoprotein receptor-related protein 1 (LRP1) in BBB-related cells and glioma cells, we designed a novel protein nanoparticle, ferritin-HREV107-Angiopep-2 (Fn-Rev-Ang). We found that Fn-Rev-Ang rapidly crossed the BBB in mice and had drug-loading properties. Moreover, the brain"],"journal":["ACS omega"],"pubmed_title":["Development of a Novel Dual-Order Protein-Based Nanodelivery Carrier That Rapidly Targets Low-Grade Gliomas with Microscopic Metastasis <i>in Vivo</i>."],"pmcid":["PMC7439698"],"funding_grant_id":["2018ZX09711003"],"pubmed_authors":["Zhang W","Zhong W","Lin J","Tian N","Wang Z","Zhou X","Fan S","Xu Y","Sheng F"],"additional_accession":[]},"is_claimable":false,"name":"Development of a Novel Dual-Order Protein-Based Nanodelivery Carrier That Rapidly Targets Low-Grade Gliomas with Microscopic Metastasis <i>in Vivo</i>.","description":"Clinically diagnosing low-grade gliomas and microscopic metastatic tumors in the spinal cord using magnetic resonance imaging (MRI) is challenging, as the blood-brain barrier (BBB) almost completely excludes the MRI contrast agent gadopentetate dimeglumine, GdDTPA (Magnevist), from the brain. The development of a more efficient, safe, and broad-spectrum glioma diagnosis and treatment would therefore have a great clinical value. Based on the high expression levels of both transferrin receptor 1 (TfR1) and low-density lipoprotein receptor-related protein 1 (LRP1) in BBB-related cells and glioma cells, we designed a novel protein nanoparticle, ferritin-HREV107-Angiopep-2 (Fn-Rev-Ang). We found that Fn-Rev-Ang rapidly crossed the BBB in mice and had drug-loading properties. Moreover, the brain","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Aug","modification":"2026-05-08T13:38:28.001Z","creation":"2025-06-01T02:32:42.917Z"},"accession":"S-EPMC7439698","cross_references":{"pubmed":["32832819"],"doi":["10.1021/acsomega.0c03073"]}}